Skip to main content
OpenTrials
Completed

NCT Number: NCT00707265

rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

The purpose of this study was to evaluate the rhBMP-2/CRM/CD HORIZON® Spinal System as a method of facilitating spinal fusion in patients with degenerative disc disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Degenerative Disc Disease Bone Diseases Intervertebral Disc Degeneration Musculoskeletal Diseases Spinal Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Barrow Neurosurgical Associates, Phoenix, Arizona, United States

Loading trial locations.

About this study

This clinical trial was conducted to evaluate the rhBMP-2/CRM/CD HORIZON® Spinal System for posterolateral fusion treatment of patients with symptomatic degenerative disc disease versus the control group of autogenous bone with the CD HORIZON® Spinal System.

The investigational treatment was the open bilateral posterolateral implantation of the rhBMP-2/CRM/CD HORIZON® Spinal System. One investigational implant was placed across two adjacent transverse processes on each side of the spine during the spinal fusion procedure.

The control treatment was the bilateral posterolateral implantation of the autogenous bone harvested from the iliac crest with the CD HORIZON® Spinal System.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Each patient participating in this clinical trial must meet all of the following inclusion criteria:

  • Has degenerative disc disease as noted by back pain of discogenic origin, with or without leg pain, with degeneration of the disc confirmed by patient history of pain and radiographic studies:
  • Requires fusion of a single level disc space from L1 to S1.
  • Has not responded to non-operative treatment (e.g., bed rest, physical therapy, medications, spinal injections, manipulation, and/or TENS) for a period of 6 months.
  • If of child-bearing potential, patient is non-pregnant, non-nursing, and agrees to use adequate contraception for 1 year following surgery.

Exclusion criteria

A patient meeting any of the following criteria is to be excluded from this clinical trial:

  • Has primary diagnosis of a spinal disorder other than degenerative disc disease with Grade 1 or less spondylolisthesis at the involved level.
  • Had previous spinal fusion surgical procedure at the involved level.
  • Requires spinal fusion at more than one lumbar level.
  • Has been previously diagnosed with osteopenia.
  • Has presence of active malignancy or prior history of malignancy (except for basal cell carcinoma of the skin).
  • Has a history of autoimmune disease (e.g. Systemic Lupus Erythematosus or dermatomyositis).
  • Has a history of exposure to injectable collagen or silicone implants.
  • Has received treatment with an investigational therapy within 28 days prior to implantation surgery or such treatment is planned during the 16 weeks following rhBMP 2/CRM implantation.
  • Has received any previous exposure to any/all BMP's of either human or animal extraction.

Treatment and study plan

rhBMP-2/CRM/CD HORIZON® Spinal System

Device

The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.

The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used.

Other names: rhBMP-2, CRM, CD HORIZON® Spinal System

Autograft/CD HORIZON® Spinal System

Device

The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.

Other names: Autograft, CD HORIZON® Spinal System

Primary outcomes

  1. Overall Success

    Time frame: 24 months

    A patient will be considered an overall success if all of the following conditions are met:

    • fusion;
    • pain/disability (Oswestry) improvement;
    • maintenance or improvement in neurological status;
    • no serious adverse event classified as implant associated or implant/surgical procedure associated;
    • no additional surgical procedure classified as a "failure."

Secondary outcomes

  1. Fusion

    Time frame: 24 months

    Fusion is defined as:

    • Evidence of bridging trabecular bone.
    • No evidence of motion.
    • Absence of cracking, as evidenced by radiolucent lines completely through the fusion mass.

  2. Pain/Disability Status

    Time frame: 24 months

    The self-administered Oswestry Low Back Pain Disability Questionnaire will be used. Success will be defined as pain/disability improvement postoperatively according to the definition: Preoperative Score - Postoperative Score >= 15 points

  3. Overall Neurological Status

    Time frame: 24 months

    Neurological status will be assessed preoperatively and postoperatively using a neurological status scale. Neurological status is based on four types of measurements (sections): motor, sensory, reflexes, and straight leg raise. Overall measure of neurological status will be based on success statuses in the four parameters.

  4. General Health Status

    Time frame: 24 months

    The Medical Outcomes Study 36-item Short Form Health Survey (SF-36) will be used to assess general health status. The SF-36 results can be summarized into two components, a physical component summary (PCS) and a mental component summary (MCS). Success will be defined as a maintenance or improvement in status postoperatively as compared to the preoperative condition. To be classified as a success, the following criteria must be met:

    PCSPostop - PCSPreop >= 0; MCSPostop - MCSPreop >= 0

  5. Back Pain

    Time frame: 24 months

    Numerical rating scales will be used to evaluate pain intensity and duration. The pain score (0 min, 20 Max) is derived by adding the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and duration scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Success for back and leg pain is described as follows:

    Preoperative Score - Postoperative Score >=0

  6. Leg Pain

    Time frame: 24 months

    Numerical rating scales will be used to evaluate pain intensity and duration. The pain score (0 min, 20 Max) is derived by adding the numerical rating scores from the pain intensity (0-10, with a score of 0 representing "no pain" and a score of 10 representing "pain as bad as it could be.") and duration scales (0-10, with a score of 0 being "pain none of the time" and a score of 10 being "pain all of the time"). Success for back and leg pain is described as follows:

    Preoperative Score - Postoperative Score >=0

  7. Operative Time

    Time frame: At the time of operation

  8. Blood Loss

    Time frame: At the time of operation

  9. Hospital Days

    Time frame: At the time of discharge

Sponsors and collaborators

Lead sponsor

Medtronic Spinal and Biologics

Industry

Registry information

Official study title

A Prospective, Randomized Clinical Investigation of rhBMP-2 and Compression Resistant Matrix With the CD HORIZON® Spinal System for Posterolateral Lumbar Fusion in Patients With Symptomatic Degenerative Disc Disease

Acronym: CRM

Important dates

Study start
2002
Primary completion
2005
Study completion
2010
First posted
Jun 30, 2008
Registry last updated
May 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.